Brief: Effector Therapeutics Received A Letter From Nasdaq Stating That Co Has Regained Compliance With Minimum Bid Price Requirement
Jan 30 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS INC - ON JANUARY 29, RECEIVED A
LETTER
FROM NASDAQ STATING THAT CO HAS REGAINED COMPLIANCE WITH MINIMUM
BID PRICE REQUIREMENT
Source text for Eikon: ID:n0001193125-24-018799
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright